Your browser doesn't support javascript.
loading
Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).
Dunkel, Ira J; Piao, Jin; Chantada, Guillermo L; Banerjee, Anuradha; Abouelnaga, Sherif; Buchsbaum, Jeffrey C; Merchant, Thomas E; Granger, Meaghan M; Jubran, Rima F; Weinstein, Joanna L; Saguilig, Lauren; Abramson, David H; Krailo, Mark D; Rodriguez-Galindo, Carlos; Chintagumpala, Murali M.
Afiliación
  • Dunkel IJ; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Piao J; University of Southern California, Los Angeles, CA.
  • Chantada GL; Hospital de Pediatria SAMIC, Prof Dr Juan P Garrahan, Buenos Aires, Argentina.
  • Banerjee A; UCSF Medical Center, San Francisco, CA.
  • Abouelnaga S; Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
  • Buchsbaum JC; National Cancer Institute, Bethesda, MD.
  • Merchant TE; St Jude Children's Research Hospital, Memphis, TN.
  • Granger MM; Cook Children's Hospital, Fort Worth, TX.
  • Jubran RF; Children's Hospital Los Angeles, Los Angeles, CA.
  • Weinstein JL; Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • Saguilig L; Children's Oncology Group, Monrovia, CA.
  • Abramson DH; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Krailo MD; University of Southern California, Los Angeles, CA.
  • Rodriguez-Galindo C; St Jude Children's Research Hospital, Memphis, TN.
  • Chintagumpala MM; Texas Children's Hospital, Houston, TX.
J Clin Oncol ; 40(33): 3839-3847, 2022 11 20.
Article en En | MEDLINE | ID: mdl-35820112
PURPOSE: Metastatic retinoblastoma has a poor prognosis when treated with conventional chemotherapy and radiation therapy (RT). Intensified therapy may improve the outcome. METHODS: A prospective, international trial enrolled patients with extraocular retinoblastoma. Patients with stage II or III (locoregional) retinoblastoma received four cycles of chemotherapy, followed by involved field RT (45 Gy). Patients with stage IVa or IVb (metastatic or trilateral) retinoblastoma also received four cycles of chemotherapy and those with ≥ partial response then received one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support. Patients with stage IVa or IVb with residual tumor postchemotherapy received RT. The proportion of patients who achieved event-free survival would be reported and compared with historical controls separately for each of the three groups of patients. RESULTS: Fifty-seven eligible patients were included in the analyses. Event-free survival at 1 year was 88.1% (90% CI, 66.6 to 96.2) for stage II-III, 82.6% (90% CI, 61.0 to 92.9) for stage IVa, and 28.3% (90% CI, 12.7 to 46.2) for stage IVb/trilateral. Toxicity was significant as expected and included two therapy-related deaths. CONCLUSION: Intensive multimodality therapy is highly effective for patients with regional extraocular retinoblastoma and stage IVa metastatic retinoblastoma. Although the study met its aim for stage IVb, more effective therapy is still required for patients with CNS involvement (ClinicalTrials.gov identifier: NCT00554788).
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinoblastoma / Neoplasias de la Retina Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Retinoblastoma / Neoplasias de la Retina Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos